The current state of the art for biological therapies and new small molecules in inflammatory bowel disease

ACG Clinical Guideline: Management of Crohn’s Disease in Adults

(2018) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders

(2018) Robert P. Hirten et al.   Clinical Gastroenterology and Hepatology

A Spectrum of Genetic Variants Contributes to Immune Defects and Pathogenesis of Inflammatory Bowel Diseases

(2018) Holm H. Uhlig et al.   GASTROENTEROLOGY

Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease

(2018) Omoniyi J. Adedokun et al.   GASTROENTEROLOGY

Analysis of Genes Associated With Monogenic Primary Immunodeficiency Identifies Rare Variants in XIAP in Patients With Crohn’s Disease

(2018) Leila Amininejad et al.   GASTROENTEROLOGY

Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn’s Disease

(2018) Brian G. Feagan et al.   GASTROENTEROLOGY

DOP054 Vedolizumab in combination with steroids for induction therapy in Crohn’s disease: an exploratory analysis of the GEMINI 2 and GEMINI 3 studies

(2018) B E Sands et al.   Journal of Crohns & Colitis

OP006 Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study

(2018) S Danese et al.   Journal of Crohns & Colitis

DOP049 Combination therapy of cyclosporine and vedolizumab is effective and safe for severe, steroid-resistant ulcerative colitis patients: A prospective study

(2018) D Tarabar et al.   Journal of Crohns & Colitis

Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation

(2018) Scott M. Whitlock et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

A presentation of ulcerative colitis after rituximab therapy in a patient with multiple sclerosis and literature review

(2018) Sareh Shahmohammadi et al.   Multiple Sclerosis and Related Disorders

Infliximab Concentration Thresholds During Maintenance Therapy Vary Based on the Therapeutic Outcome of Interest in Inflammatory Bowel Disease

(2017) Shana Rakowsky et al.   GASTROENTEROLOGY

ANTI-PD-1 Induced Colitis: A Case Series of 25 Patients

(2017) James Kim et al.   GASTROENTEROLOGY

Efficacy and Safety of Abrilumab in Subjects with Moderate to Severe Ulcerative Colitis: Results of a Phase 2B, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study

(2017) William J. Sandborn et al.   GASTROENTEROLOGY

American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases

(2017) Niels Vande Casteele et al.   GASTROENTEROLOGY

Higher Levels of Infliximab may Alleviate the Need of Azathioprine Comedication in the Treatment of Patients with Crohn's Disease: A Sonic Post HOC Analysis

(2017) Jean Frederic Colombel et al.   GASTROENTEROLOGY

Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases

(2017) Jean-Frederic Colombel et al.   GASTROENTEROLOGY

Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases

(2017) Clara Abraham et al.   GASTROENTEROLOGY

Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease

(2017) Jeffrey S. Hyams et al.   GASTROENTEROLOGY

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study

(2017) Bruce E. Sands et al.   GASTROENTEROLOGY

Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest

(2017) William J. Sandborn et al.   GASTROENTEROLOGY

Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease

(2017) Magali Lemaitre et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease

(2017) L.C.S. De Vries et al.   Journal of Crohns & Colitis

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

(2017) Marcus Harbord et al.   Journal of Crohns & Colitis

Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials

(2017) Kristian Reich et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

(2017) Séverine Vermeire et al.   LANCET

Crohn's disease

(2017) Joana Torres et al.   LANCET

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

(2017) Jean-Frederic Colombel et al.   LANCET

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

(2017) Séverine Vermeire et al.   LANCET

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

(2017) Brian G Feagan et al.   LANCET

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

(2017) Kristin K Jørgensen et al.   LANCET

Ulcerative colitis

(2017) Ryan Ungaro et al.   LANCET

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

(2017) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab-induced Crohn’s disease

(2017) Poornima Varma et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Clinical Genomics in Inflammatory Bowel Disease

(2017) Holm H. Uhlig et al.   TRENDS IN GENETICS

Ustekinumab and Anti-TNF Combination Therapy in Patients with Inflammatory Bowel Disease

(2016) Clara Yzet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease

(2016) Stephan R Targan et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines

(2016) Silvio Danese et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation

(2016) Shomron Ben-Horin et al.   Clinical Gastroenterology and Hepatology

Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis

(2016) Gaik W. Tew et al.   GASTROENTEROLOGY

The safety of vedolizumab for ulcerative colitis and Crohn's disease

(2016) Jean-Frédéric Colombel et al.   GUT

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

(2016) Fernando Gomollón et al.   Journal of Crohns & Colitis

Integrin-based therapeutics: biological basis, clinical use and new drugs

(2016) Klaus Ley et al.   NATURE REVIEWS DRUG DISCOVERY

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

(2016) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic review: colitis associated with anti-CTLA-4 therapy

(2015) A. Gupta et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables

(2015) C. A. Siegel et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn’s Disease

(2015) Robert Hirten et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

(2015) L Peyrin-Biroulet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up

(2015) R.G. Langley et al.   BRITISH JOURNAL OF DERMATOLOGY

Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn’s Disease and Effects of Natalizumab Therapy

(2015) Emanuelle Bellaguarda et al.   Clinical Gastroenterology and Hepatology

The Pharmacokinetics of Biologics: A Primer

(2015) Diane R. Mould   DIGESTIVE DISEASES

Apremilast: A Review in Psoriasis and Psoriatic Arthritis

(2015) Emma D. Deeks   DRUGS

Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events

(2015) Reena Khanna et al.   Expert Opinion On Drug Safety

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

(2015) Niels Vande Casteele et al.   GASTROENTEROLOGY

Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease

(2015) Joana Torres et al.   GASTROENTEROLOGY

Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation

(2015) Joseph R. Maxwell et al.   IMMUNITY

Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease

(2015) Carlos Fernandes et al.   Immunotherapy

Introducing Vedolizumab to Clinical Practice: Who, When, and How?

(2015) RV Bryant et al.   Journal of Crohns & Colitis

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort

(2015) Krisztina B. Gecse et al.   Journal of Crohns & Colitis

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

(2015) Kim Papp et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Crohn's disease management after intestinal resection: a randomised trial

(2015) Peter De Cruz et al.   LANCET

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

(2015) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease

(2015) Giovanni Monteleone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy

(2015) B. Lo et al.   SCIENCE

Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea

(2015) Sang Hyoung Park et al.   Expert Review of Gastroenterology & Hepatology

Catching the Therapeutic Window of Opportunity in Early Crohn’s Disease

(2014) Silvio Danese et al.   CURRENT DRUG TARGETS

Biologics for Extraintestinal Manifestations of IBD

(2014) Stephan Vavricka et al.   CURRENT DRUG TARGETS

The Diagnostic Approach to Monogenic Very Early Onset Inflammatory Bowel Disease

(2014) Holm H. Uhlig et al.   GASTROENTEROLOGY

Association Between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients With Inflammatory Bowel Disease

(2014) Nynne Nyboe Andersen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

(2014) Séverine Vermeire et al.   LANCET

Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations

(2014) Desirée Schubert et al.   NATURE MEDICINE

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sphingosine-1-Phosphate and Its Receptors: Structure, Signaling, and Influence

(2013) Hugh Rosen et al.   Annual Review of Biochemistry

Targeting T and B Lymphocytes in Inflammatory Bowel Diseases: Lessons from Clinical Trials

(2013) R.R. Gerner et al.   DIGESTIVE DISEASES

Lymphoma: The Bête Noire of the Long-term Use of Thiopurines in Adult and Elderly Patients With Inflammatory Bowel Disease

(2013) Laurent Beaugerie   GASTROENTEROLOGY

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

(2013) Remo Panaccione et al.   GASTROENTEROLOGY

Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

α4β7integrin: beyond T cell trafficking

(2013) Sarah L Kempster et al.   GUT

The Cytotoxic Effects of Certolizumab Pegol and Golimumab Mediated by Transmembrane Tumor Necrosis Factor α

(2013) Naoyasu Ueda et al.   INFLAMMATORY BOWEL DISEASES

ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)

(2013) Silvio Danese et al.   Journal of Crohns & Colitis

Extra-intestinal malignancies in inflammatory bowel disease: Results of the 3rd ECCO Pathogenesis Scientific Workshop (III)

(2013) Fernando Magro et al.   Journal of Crohns & Colitis

IL-23R+ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism

(2013) A Eken et al.   Mucosal Immunology

Dynamic regulatory network controlling TH17 cell differentiation

(2013) Nir Yosef et al.   NATURE

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Severe Early-Onset Colitis Revealing Mevalonate Kinase Deficiency

(2013) M. Levy et al.   PEDIATRICS

Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry

(2012) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial

(2012) Paul Rutgeerts et al.   GASTROENTEROLOGY

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol

(2012) Xavier Hébuterne et al.   GUT

Mucosal healing in inflammatory bowel diseases: a systematic review

(2012) Markus F Neurath et al.   GUT

Secukinumab failure in Crohn's disease: the yeast connection?

(2012) Jean Frédéric Colombel et al.   GUT

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

(2012) Wolfgang Hueber et al.   GUT

Response to biologic therapy in Crohnʼs disease is improved with early treatment: An analysis of health claims data

(2012) David T. Rubin et al.   INFLAMMATORY BOWEL DISEASES

Neutralization of Membrane TNF, but Not Soluble TNF, Is Crucial for the Treatment of Experimental Colitis

(2012) Clémentine Perrier et al.   INFLAMMATORY BOWEL DISEASES

IL-17 and TNF-  Sustain Neutrophil Recruitment during Inflammation through Synergistic Effects on Endothelial Activation

(2012) G. K. Griffin et al.   JOURNAL OF IMMUNOLOGY

Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial

(2012) David Laharie et al.   LANCET

Induction and molecular signature of pathogenic TH17 cells

(2012) Youjin Lee et al.   NATURE IMMUNOLOGY

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical, serological and genetic predictors of inflammatory bowel disease course

(2012) Laurent Beaugerie   WORLD JOURNAL OF GASTROENTEROLOGY

Inhibitory Smad7: Emerging Roles in Health and Disease

(2012) Marco A. Briones-Orta et al.   Current Molecular Pharmacology

Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: Results from a randomized controlled trial

(2011) Maria W. Greenwald et al.   ARTHRITIS AND RHEUMATISM

A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes

(2011) EG Stefanich et al.   BRITISH JOURNAL OF PHARMACOLOGY

Rituximab in Active Ulcerative Colitis

(2011) Elisabeth Calderón–Gómez et al.   GASTROENTEROLOGY

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

(2011) Edouard Louis et al.   GASTROENTEROLOGY

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis

(2011) K. Leiper et al.   GUT

Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease

(2011) Jean-Frédéric Colombel et al.   INFLAMMATORY BOWEL DISEASES

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials

(2011) Kenneth B. Gordon et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Biosimilar, biobetter and next generation therapeutic antibodies

(2011) Alain Beck   mAbs

Mevalonate Kinase Deficiency: A Survey of 50 Patients

(2011) B. Bader-Meunier et al.   PEDIATRICS

Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity

(2011) A. Puel et al.   SCIENCE

Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease - subgroup results from a placebo-controlled study

(2010) S. Schreiber et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Response?

(2010) Geert R D'Haens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Interleukin-23 Drives Intestinal Inflammation through Direct Activity on T Cells

(2010) Philip P. Ahern et al.   IMMUNITY

Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology

(2010) Sofia Buonocore et al.   NATURE

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regulation of TGF-  signaling by Smad7

(2009) X. Yan et al.   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

Influence of Phenotype at Diagnosis and of Other Potential Prognostic Factors on the Course of Inflammatory Bowel Disease

(2009) M J L Romberg-Camps et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Interleukin-23/Th17 pathways and inflammatory bowel disease

(2009) Clara Abraham et al.   INFLAMMATORY BOWEL DISEASES

Impact of prior irregular infliximab dosing on performance of long-term infliximab maintenance therapy in Crohnʼs disease†

(2009) Daniel J. Stein et al.   INFLAMMATORY BOWEL DISEASES

A protective function for interleukin 17A in T cell–mediated intestinal inflammation

(2009) William O'Connor Jr et al.   NATURE IMMUNOLOGY

Hepatosplenic T cell lymphoma in inflammatory bowel disease

(2008) M. Shale et al.   GUT

Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease

(2008) D. E. Fassi et al.   GUT

Innate and Adaptive Interleukin-22 Protects Mice from Inflammatory Bowel Disease

(2008) Lauren A. Zenewicz et al.   IMMUNITY

A review of the current use of rituximab in autoimmune diseases

(2008) Hakan M. Gürcan et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

The comeback kid: TYSABRI now FDA approved for Crohn disease

(2008) Karen Honey   JOURNAL OF CLINICAL INVESTIGATION

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

(2008) Geert D'Haens et al.   LANCET